Chen Mengping, Jiang Jinxing, Hou Jian
Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Biomark Res. 2023 May 31;11(1):55. doi: 10.1186/s40364-023-00502-8.
Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of plasma cells. Although therapeutic advances have been made to improve clinical outcomes and to prolong patients' survival in the past two decades, MM remains largely incurable. Single-cell sequencing (SCS) is a powerful method to dissect the cellular and molecular landscape at single-cell resolution, instead of providing averaged results. The application of single-cell technologies promises to address outstanding questions in myeloma biology and has revolutionized our understanding of the inter- and intra-tumor heterogeneity, tumor microenvironment, and mechanisms of therapeutic resistance in MM. In this review, we summarize the recently developed SCS methodologies and latest MM research progress achieved by single-cell profiling, including information regarding the cancer and immune cell landscapes, tumor heterogeneities, underlying mechanisms and biomarkers associated with therapeutic response and resistance. We also discuss future directions of applying transformative SCS approaches with contribution to clinical translation.
多发性骨髓瘤（MM）是一种以浆细胞克隆性增殖为特征的血液系统恶性肿瘤。尽管在过去二十年中治疗取得了进展，改善了临床结局并延长了患者生存期，但MM在很大程度上仍然无法治愈。单细胞测序（SCS）是一种能够在单细胞分辨率下剖析细胞和分子格局的强大方法，而非提供平均结果。单细胞技术的应用有望解决骨髓瘤生物学中悬而未决的问题，并彻底改变了我们对肿瘤间和肿瘤内异质性、肿瘤微环境以及MM治疗耐药机制的理解。在这篇综述中，我们总结了最近开发的SCS方法以及通过单细胞分析取得的MM最新研究进展，包括有关癌症和免疫细胞格局、肿瘤异质性、与治疗反应和耐药相关的潜在机制和生物标志物的信息。我们还讨论了应用变革性SCS方法促进临床转化的未来方向。
